Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.

Abstract : INTRODUCTION: In the literature, data on the effect of renal impairment on the pharmacokinetics of anticancer drugs are scarce. Here, we report a 68-year-old metastatic osteosarcoma patient with impaired renal function due to prior chemotherapy, who was treated on compassionate use basis with 400 mg/m(2) cetuximab. MATERIAL AND METHODS: Pharmacokinetic parameters after the first dose, including dose-normalised AUC from time zero to day 7, clearance, elimination half-life (t 1/2), were estimated using trapezoidal non-compartmental methods and compared to pharmacokinetic data from a study population with normal kidney function. RESULTS: The results showed that the pharmacokinetics of cetuximab in this patient with renal failure was similar to that with adequate renal function. CONCLUSION: This study suggests that cetuximab can be safely used in cancer patients with renal impairment without dose adjustment.
Type de document :
Article dans une revue
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2014, epub ahead of print. 〈10.1007/s00280-014-2462-4〉
Liste complète des métadonnées

Littérature citée [2 références]  Voir  Masquer  Télécharger

https://hal-univ-tours.archives-ouvertes.fr/hal-00992023
Contributeur : Gilles Paintaud <>
Soumis le : vendredi 16 mai 2014 - 11:27:01
Dernière modification le : vendredi 22 juin 2018 - 17:08:05
Document(s) archivé(s) le : samedi 16 août 2014 - 11:46:32

Fichier

Submitted_manuscript_-_pharmac...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

L. L. Krens, J. M. Baas, M. C. Verboom, G. Paintaud, C. Desvignes, et al.. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.. Cancer Chemotherapy and Pharmacology, Springer Verlag, 2014, epub ahead of print. 〈10.1007/s00280-014-2462-4〉. 〈hal-00992023〉

Partager

Métriques

Consultations de la notice

284

Téléchargements de fichiers

471